Carregant...
Both cladribine and alemtuzumab may effect MS via B-cell depletion
OBJECTIVE: To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies. METHODS: The regulatory submissions of the CLAD Tablets Treating Multiple...
Guardat en:
| Publicat a: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Lippincott Williams & Wilkins
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5459792/ https://ncbi.nlm.nih.gov/pubmed/28626781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000360 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|